Pattern of Cortical Thickness in Depression Among Early-stage Parkinson's Disease: A Potential Neuroimaging Indicator for Early Recognition

Behavioural Brain Research, Год журнала: 2025, Номер unknown, С. 115622 - 115622

Опубликована: Май 1, 2025

Язык: Английский

---

Serotonin Mitigates Depression in a rotenone-induced mouse Parkinson’s Disease model by Inhibiting hippocampal Neuronal Pyroptosis and Neuroinflammation

Behavioural Brain Research, Год журнала: 2025, Номер unknown, С. 115620 - 115620

Опубликована: Май 1, 2025

Язык: Английский

---

Ultra-sensitive UHPLC-MS/MS method for simultaneous quantification of 31 neurochemicals in zebrafish larvae and brain

Talanta, Год журнала: 2025, Номер 295, С. 128334 - 128334

Опубликована: Май 14, 2025

Язык: Английский

---

Depressive symptoms interact with CSF levels of p-tau in predicting cognitive performance in the early stages of Parkinson’s disease

Journal of Psychiatric Research, Год журнала: 2025, Номер 188, С. 87 - 93

Опубликована: Май 23, 2025

Язык: Английский

---

Approaches for treating neuropsychiatric symptoms in Parkinson’s disease: a narrative review

Therapeutic Advances in Neurological Disorders, Год журнала: 2025, Номер 18

Опубликована: Янв. 1, 2025

Neuropsychiatric symptoms in Parkinson’s disease (PD) are highly prevalent and profoundly disabling, often emerging even before the onset of motor symptoms. As progresses, these usually become increasingly impairing now recognized as having greatest impact on quality life not only for patients but also caregivers. In recent years, there have been significant advances diagnosis management neuropsychiatric However, still substantial gaps therapeutic approaches algorithms, with limited pharmacological nonpharmacological treatment options currently available. One main reasons this is complex molecular neural bases symptoms, which involve both dopaminergic nondopaminergic neurotransmission systems extend far beyond nigrostriatal pathway. a result, drugs recommended treating PD few supported by evidence. context, experience neurologist remains critical selecting most appropriate individualized therapy. The aim paper to review available provide an overview current research efforts, particularly those focusing treatments.

Язык: Английский

---

Genetic Insights into the Molecular Pathophysiology of Depression in Parkinson’s Disease

Medicina, Год журнала: 2023, Номер 59(6), С. 1138 - 1138

Опубликована: Июнь 13, 2023

Background and Objectives: Parkinson’s disease (PD) is a clinically heterogeneous disorder with poorly understood pathological contributing factors. Depression presents one of the most frequent non-motor PD manifestations, several genetic polymorphisms have been suggested that could affect depression risk in PD. Therefore, this review we collected recent studies addressing role factors development PD, aiming to gain insights into its molecular pathobiology enable future targeted effective treatment strategies. Materials Methods: searched PubMed Scopus databases for peer-reviewed research articles published English (pre-clinical clinical as well relevant reviews meta-analyses) investigating architecture pathophysiology depression. Results: particular, genes related serotoninergic pathway (sodium-dependent serotonin transporter gene, SLC6A4, tryptophan hydrolase-2 TPH2), dopamine metabolism neurotransmission (dopamine receptor D3 DRD3, aldehyde dehydrogenase 2 ALDH2), neurotrophic (brain-derived factor BDNF), endocannabinoid system (cannabinoid CNR1), circadian rhythm (thyrotroph embryonic TEF), sodium-dependent neutral amino acid B(0)AT2 SLC6A15), PARK16 locus were detected altering susceptibility among patients. However, gene (SLC6A3), monoamine oxidase A (MAOA) B (MAOB) genes, catechol-O-methyltransferase (COMT), CRY1, CRY2 not Conclusions: specific mechanisms underlying potential diversity are still under investigation, however, there evidence they may involve neurotransmitter imbalance, mitochondrial impairment, oxidative stress, neuroinflammation, dysregulation their downstream signaling pathways.

Язык: Английский

---

Analysis of MicroRNA-Transcription Factors Co-Regulatory Network Linking Depression and Vitamin D Deficiency

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(2), С. 1114 - 1114

Опубликована: Янв. 17, 2024

Depression and vitamin D deficiency are often co-occurring pathologies, the common pathogenetic ground of which includes an augmented inflammatory response. However, molecular details this relationship remain unclear. Here, we used a bioinformatic approach to analyze GEO transcriptome datasets major depressive disorder (MDD) (VDD) identify hub genes within regulatory networks commonly differentially expressed (DEGs). The MDD-VDD shared network contains 100 DEGs (71 upregulated 29 downregulated), with six (PECAM1, TLR2, PTGS2, LRRK2, HCK, IL18) all significantly upregulated, PTGS2 (also known as COX2) shows highest inference score reference count. subsequent analysis miRNA-transcription factors identified COX2, miR-146a-5p, miR-181c-5p key co-regulatory actors in pathogenic mechanisms. Subsequent published MDD VDD data confirmed importance genes, further validating our analytical pipeline. Our study demonstrated that was highly both patients low plasma levels. Therefore, regulators targeting like miR-146a-5p miR181c-5p, may have great potential controlling diseases simultaneously, accentuating their role future research.

Язык: Английский

---

Potential Impact of Hypoxic Astrocytes on the Aggravation of Depressive Symptoms in Parkinson’s Disease

Journal of Molecular Neuroscience, Год журнала: 2024, Номер 74(1)

Опубликована: Март 5, 2024

Язык: Английский

---

The effects of paroxetine therapy on depressive symptom and motor function in the treatment of depression with Parkinson’s disease: A meta-analysis

Medicine, Год журнала: 2023, Номер 102(34), С. e34687 - e34687

Опубликована: Авг. 25, 2023

Paroxetine therapy has been used for treatment of patients with depression and Parkinson's disease (dPD) in many clinical studies, but, the effects paroxetine dPD are not completely understood. The aim this study was to systematically evaluate on depressive symptom motor function dPD, order confer a reference practice.Randomized controlled trials (RCTs) published up October, 2022 were retrieved. Standardised mean difference (SMD), odds ratio (OR), 95% confidence interval (CI) calculated heterogeneity measured I2 test. outcomes interest as follows: efficacy, Hamilton rating scale score, unified anxiety score or adverse events.Thirty-four RCTs 2819 participants included. Compared control group, pooled (22 trials; OR 3.62, CI 2.63 4.98, P < .00001) antidepressant response (25 SMD -2.14, -2.73 -1.56, (10 4.63, 3.15 6.79, anti-PD efficacy (18 -2.02, -2.48 -1.55, total score. showed significant decrease group compared -1.93, -2.65 -1.22, .00001). In addition, reduced number any events obviously (twenty 0.42, 0.31 0.57, .00001).Paroxetine benefits improvement patients, moreover, it is high drug safety. Further well-designed, multi-center needed identify these findings.

Язык: Английский

---

Epigenetic insights into neuropsychiatric and cognitive symptoms in Parkinson's disease: A DNA co-methylation network analysis

Research Square (Research Square), Год журнала: 2023, Номер unknown

Опубликована: Сен. 21, 2023

Abstract Parkinson’s disease is a highly heterogeneous disorder, encompassing complex spectrum of clinical presentation including motor, sleep, cognitive and neuropsychiatric symptoms. We aimed to investigate genome-wide DNA methylation networks in post-mortem brain samples test for region-specific association with common Of traits tested, we identify co-methylation module the substantia nigra significant correlation depressive symptoms ontological enrichment terms relevant neuronal synaptic processes. Notably, expression genes annotated loci present within this are found be significantly enriched subtypes nigra. These findings highlight potential involvement neuronal-specific changes regard disease.

Язык: Английский

---